ClinicalTrials.gg
CompletedNCT01119937GLOW4Updated Jan 18, 2013Results posted

Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients

A Phase 3 interventional study of NVA237 and Tiotropium in Chronic Obstructive Pulmonary Disease, sponsored by Novartis Pharmaceuticals. Completed at 40 sites in Japan. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2013-01-18.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
211
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
34th of 73
211 · median 152
Started
2010
with 4 others
Phase 3
33 of 73
1 open now
Registered
11th of 73
by date
Lead sponsor
19 of 73
Novartis Pharmaceuticals

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 34th largest by enrollment, is one of 5 that started in 2010, is one of 33 in phase 3, and was the 11th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This is a 52-week, multi-center, randomized, open label, parallel group study to assess the long term safety and tolerability of once-daily NVA237, using tiotropium as an active control, in Japanese patients with moderate to severe chronic obstructive pulmonary disease (COPD) .

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • COPD
  • NVA237
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with moderate to severe stable (Stage II or Stage III) according to the Gold Guideline 2008.
  • Current or ex-smokers who have a smoking history of at least 10 pack years.
  • Patients with a post-bronchodilator ≥30% and \< 80% of the predicted normal, and postbronchodilator FEV1/FVC \< 0.7 at Visit 2 (day -7)

Exclusion criteria

Exclusion Criteria:

  • Pregnant women or nursing mothers or women of not using an acceptable method of
  • Patients requiring long term oxygen therapy
  • Patients who have had a lower respiratory tract infection within 6 weeks prior to Visit 1
  • Patients with concomitant pulmonary disease
  • Patients with a history of asthma
  • Any patient with lung cancer or a history of lung cancer
  • Patients with a history of certain cardiovascular comorbid conditions
  • Patients with a known history and diagnosis of alpha-1 antitrypsin deficiency
  • Patients in the active phase of a supervised pulmonary rehabilitation program
  • Patients for tiotropium or ipratropium treatment or who have shown an untoward reaction to inhaled anticholinergic agents
  • Other protocol-defined inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
211 participants (actual)

Study arms

  • Experimental
    NVA237

    50µg once daily

    Drug: NVA237

  • Experimental
    Tiotropium

    18µg once daily

    Drug: Tiotropium

Interventions

  • DrugNVA237

    50µg capsules for inhalation, delivered via a single dose dry powder inhaler (Concept 1®)

  • 18µg capsules for inhalation, delivered via HandiHaler®

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events, Serious Adverse Events or Death

    Adverse events are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal lab finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgments of the investigators represent significant hazards.

    Time frame: 52 weeks

Secondary outcomes

  1. Change in Pre-dose FEV1 From Baseline

    Pre-dose FEV1 is defined as the average of the measurements at 45 and 15 minutes pre-dose.

    Time frame: Weeks 12, 24, 36 and 52

  2. Change in Pre-dose FVC From Baseline

    Pre-dose FVC is defined as the average of the measurements at 45 and 15 minutes pre-dose.

    Time frame: Weeks 12, 24, 36 and 52

  3. Time From Randomization Until the Start of the First Moderate or Severe COPD Exacerbation

    Moderate COPD exacerbations were defined as: worsening of 2 or more of the following major symptoms for at least 2 consecutive days - dyspnea, sputum volume and sputum purulence; OR a worsening of any 1 major symptom with any 1 of the following minor symptoms for at least 2 consecutive days - sore throat, colds, fever without other cause, increased cough or increased wheeze, requiring treatment with systemic glucocorticosteroids or antibiotics or both. Severe COPD exacerbations were defined as: conditions for Moderate COPD exacerbation and hospitalization was required. Participants who withdraw from the study and do not experience a moderate or severe exacerbation are censored at the date of withdrawal. Participants who complete the study and do not experience a moderate or severe exacerbation are censored at the completion visit date.

    Time frame: 52 weeks

  4. Number of Patients With Moderate or Severe COPD Exacerbations

    Moderate COPD exacerbations were defined as: worsening of 2 or more of the following major symptoms for at least 2 consecutive days - dyspnea, sputum volume and sputum purulence; OR a worsening of any 1 major symptom with any 1 of the following minor symptoms for at least 2 consecutive days - sore throat, colds, fever without other cause, increased cough or increased wheeze, requiring treatment with systemic glucocorticosteroids or antibiotics or both. Severe COPD exacerbations were defined as: conditions for Moderate COPD exacerbation and hospitalization was required.

    Time frame: 52 weeks

  5. Change in St. George Respiratory Questionnaire From Baseline

    SGRQ is a health related quality of life questionnaire consisting of 51 items in three components: symptoms, activity, and impacts. The lowest possible value is zero and the highest 100. Higher values correspond to greater impairment in quality of life.

    Time frame: Weeks 12, 24, 36, 52

  6. Change From Baseline in Mean Daily Number of Puffs of Rescue Medication Over the Whole Treatment Period

    Patients recorded rescue medication use in a paper patient diary. If a patient required the use of salbutamol as rescue medication due to an increase in COPD symptoms, the number of inhalations (puffs) taken was recorded in the patient diary.

    Time frame: 52 weeks

  7. Number of Patients With Newly Occurring or Worsening Clinically Notable Hematology Values at Any Timepoint Over the Whole Treatment Period

    Clinically notable hematology values were: hemoglobin - male \<11.5g/dL, female \<9.5 g/dL; hematocrit - male \<37%, female \<32%; white cell count - \<2800µL or \>16000µL; platelets - \<7.5 10\*4/µL or \>70.0 10\*4/µL

    Time frame: 52 weeks

  8. Number of Patients With Newly Occurring or Worsening Clinically Notable Biochemistry Values at Any Timepoint Over the Whole Treatment Period

    Clinically notable biochemistry values were: total protein - \<4.0 g/dL or \>9.5 g/dL; albumin \<2.5 g/dL; bilirubin (total) \>1.9 mg/dL; BUN \>27 mg/dL; creatinine \>1.99 mg/dL; AST \>3 x ULN U/L; ALT \>3 x ULN U/L; ALP \>3 x ULN U/L; y-GTP \>3 x ULN U/L; sodium \<125 mEq/L or \>160 mEq/L; potassium \<3.0 mEq/L or \>6.0 mEq/L; glucose \<51.0 mg/dL or \>180.0 mg/dL

    Time frame: 52 weeks

  9. Number of Patients With Newly Occurring or Worsening Clinically Notable Vital Signs Values at Any Timepoint Over the Whole Treatment Period

    Clinically notable vital sign values were: pulse rate - low, \<40 bpm or \<=50 bpm and decrease from baseline \>=15bpm; pulse rate high, \>130 bpm or \>=120bpm and increase from baseline \>=15 bpm. Systolic blood pressure - low, \<75 mmHg or \<=90 mmHg and decrease from baseline \>=20 mmHg; high, \>200 mmHg or \>=180 mmHg and increase from baseline \>=20 mmHg. Diastolic blood pressure - low, \<40 mmHg or \<=50 mmHg and decrease from baseline \>=15 mmHg; high, \>115 mmHg or \>=105 mmHg and increase from baseline \>=15 mmHg.

    Time frame: 52 weeks

  10. Number of Patients With Notable Change From Baseline in Fridericia's QTc Values at Any Timepoint Over the Whole Treatment Period

    Clinically notable change from baseline was and increase from baseline of 30 or greater milliseconds (ms).

    Time frame: 52 weeks

07

Results

Posted Jan 18, 2013

Participant flow

Participant flow — Overall Study
MilestoneNVA237Tiotropium
Started12340
Completed10433
Not completed197
Withdrew: Adverse event115
Withdrew: Protocol deviation31
Withdrew: Unsatisfactory therapeutic effect30
Withdrew: Withdrawal by subject21

Outcome measures

PrimaryNumber of Participants With Adverse Events, Serious Adverse Events or Death

Adverse events are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal lab finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgments of the investigators represent significant hazards.

Time frame:
52 weeks
Reported as:
Number · participants
Number of Participants With Adverse Events, Serious Adverse Events or Death
participantsNVA237Tiotropium
Adverse events10233
Serious adverse events166
Death00
SecondaryChange in Pre-dose FEV1 From Baseline

Pre-dose FEV1 is defined as the average of the measurements at 45 and 15 minutes pre-dose.

Time frame:
Weeks 12, 24, 36 and 52
Reported as:
Mean · liters
Change in Pre-dose FEV1 From Baseline
litersNVA237Tiotropium
Week 120.101 ± 0.14550.173 ± 0.1976
Week 240.094 ± 0.16140.144 ± 0.1435
Week 36 (n = 106, 36)0.084 ± 0.15580.112 ± 0.2200
Week 52 (n = 103, 33)0.068 ± 0.18290.127 ± 0.2566
SecondaryChange in Pre-dose FVC From Baseline

Pre-dose FVC is defined as the average of the measurements at 45 and 15 minutes pre-dose.

Time frame:
Weeks 12, 24, 36 and 52
Reported as:
Mean · liters
Change in Pre-dose FVC From Baseline
litersNVA237Tiotropium
Week 120.221 ± 0.30570.220 ± 0.3029
Week 240.218 ± 0.27980.179 ± 0.2285
Week 36 (n = 106, 36)0.208 ± 0.32040.146 ± 0.2547
Week 52 (n = 103, 33)0.195 ± 0.37390.126 ± 0.2889
SecondaryTime From Randomization Until the Start of the First Moderate or Severe COPD Exacerbation

Moderate COPD exacerbations were defined as: worsening of 2 or more of the following major symptoms for at least 2 consecutive days - dyspnea, sputum volume and sputum purulence; OR a worsening of any 1 major symptom with any 1 of the following minor symptoms for at least 2 consecutive days - sore throat, colds, fever without other cause, increased cough or increased wheeze, requiring treatment with systemic glucocorticosteroids or antibiotics or both. Severe COPD exacerbations were defined as: conditions for Moderate COPD exacerbation and hospitalization was required. Participants who withdraw from the study and do not experience a moderate or severe exacerbation are censored at the date of withdrawal. Participants who complete the study and do not experience a moderate or severe exacerbation are censored at the completion visit date.

Time frame:
52 weeks
Reported as:
Number · days
Time From Randomization Until the Start of the First Moderate or Severe COPD Exacerbation
daysNVA237Tiotropium
Time From Randomization Until the Start of the First Moderate or Severe COPD Exacerbation362 (2 to 372)359 (4 to 368)
SecondaryNumber of Patients With Moderate or Severe COPD Exacerbations

Moderate COPD exacerbations were defined as: worsening of 2 or more of the following major symptoms for at least 2 consecutive days - dyspnea, sputum volume and sputum purulence; OR a worsening of any 1 major symptom with any 1 of the following minor symptoms for at least 2 consecutive days - sore throat, colds, fever without other cause, increased cough or increased wheeze, requiring treatment with systemic glucocorticosteroids or antibiotics or both. Severe COPD exacerbations were defined as: conditions for Moderate COPD exacerbation and hospitalization was required.

Time frame:
52 weeks
Reported as:
Number · participants
Number of Patients With Moderate or Severe COPD Exacerbations
participantsNVA237Tiotropium
0 exacerbations9931
1 exacerbation175
2 exacerbations53
3 exacerbations10
> = 4 exacerbations11
SecondaryChange in St. George Respiratory Questionnaire From Baseline

SGRQ is a health related quality of life questionnaire consisting of 51 items in three components: symptoms, activity, and impacts. The lowest possible value is zero and the highest 100. Higher values correspond to greater impairment in quality of life.

Time frame:
Weeks 12, 24, 36, 52
Reported as:
Mean · score on a scale
Change in St. George Respiratory Questionnaire From Baseline
score on a scaleNVA237Tiotropium
Week 12-2.57 ± 8.506-2.31 ± 13.654
Week 24-1.77 ± 9.466-3.24 ± 12.908
Week 36-2.54 ± 9.614-0.93 ± 14.214
Week 52-2.68 ± 10.5050.36 ± 15.389
SecondaryChange From Baseline in Mean Daily Number of Puffs of Rescue Medication Over the Whole Treatment Period

Patients recorded rescue medication use in a paper patient diary. If a patient required the use of salbutamol as rescue medication due to an increase in COPD symptoms, the number of inhalations (puffs) taken was recorded in the patient diary.

Time frame:
52 weeks
Reported as:
Mean · change in puffs
Change From Baseline in Mean Daily Number of Puffs of Rescue Medication Over the Whole Treatment Period
change in puffsNVA237Tiotropium
Change From Baseline in Mean Daily Number of Puffs of Rescue Medication Over the Whole Treatment Period-0.16 ± 1.039-0.27 ± 0.859
SecondaryNumber of Patients With Newly Occurring or Worsening Clinically Notable Hematology Values at Any Timepoint Over the Whole Treatment Period

Clinically notable hematology values were: hemoglobin - male \<11.5g/dL, female \<9.5 g/dL; hematocrit - male \<37%, female \<32%; white cell count - \<2800µL or \>16000µL; platelets - \<7.5 10\*4/µL or \>70.0 10\*4/µL

Time frame:
52 weeks
Reported as:
Number · participants
Number of Patients With Newly Occurring or Worsening Clinically Notable Hematology Values at Any Timepoint Over the Whole Treatment Period
participantsNVA237Tiotropium
Hemoglobin - male (n = 121, 38)32
Hemoglobin - female (n = 121, 38)00
Hematocrit - male (n = 121, 38)34
Hematocrit - female (n = 121, 38)00
White cell count - <2800/µL01
White cell count - >16000/µL00
Platelets - <7.5 10*4/µL10
Platelets - >70.0 10*4/µL00
SecondaryNumber of Patients With Newly Occurring or Worsening Clinically Notable Biochemistry Values at Any Timepoint Over the Whole Treatment Period

Clinically notable biochemistry values were: total protein - \<4.0 g/dL or \>9.5 g/dL; albumin \<2.5 g/dL; bilirubin (total) \>1.9 mg/dL; BUN \>27 mg/dL; creatinine \>1.99 mg/dL; AST \>3 x ULN U/L; ALT \>3 x ULN U/L; ALP \>3 x ULN U/L; y-GTP \>3 x ULN U/L; sodium \<125 mEq/L or \>160 mEq/L; potassium \<3.0 mEq/L or \>6.0 mEq/L; glucose \<51.0 mg/dL or \>180.0 mg/dL

Time frame:
52 weeks
Reported as:
Number · participants
Number of Patients With Newly Occurring or Worsening Clinically Notable Biochemistry Values at Any Timepoint Over the Whole Treatment Period
participantsNVA237Tiotropium
Total protein - <4.0 g/dL00
Total protein - >9.5 g/dL00
Albumin - <2.5 g/dL00
Bilirubin (total) - >1.9 mg/dL20
BUN - >27 mg/dL30
Creatinine - >1.99 mg/dL00
AST - >3 x ULN U/L10
ALT - >3 x ULN U/L00
ALP - >3 x ULN U/L01
Y-GTP - >3 x ULN U/L54
Sodium - <125 mEq/L00
Sodium - >160 mEq/L00
Potassium - <3.0 mEq/L10
Potassium - >6.0 mEq/L00
Glucose - <51.0 mg/dL00
Glucose - >180.0 mg/dL113
SecondaryNumber of Patients With Newly Occurring or Worsening Clinically Notable Vital Signs Values at Any Timepoint Over the Whole Treatment Period

Clinically notable vital sign values were: pulse rate - low, \<40 bpm or \<=50 bpm and decrease from baseline \>=15bpm; pulse rate high, \>130 bpm or \>=120bpm and increase from baseline \>=15 bpm. Systolic blood pressure - low, \<75 mmHg or \<=90 mmHg and decrease from baseline \>=20 mmHg; high, \>200 mmHg or \>=180 mmHg and increase from baseline \>=20 mmHg. Diastolic blood pressure - low, \<40 mmHg or \<=50 mmHg and decrease from baseline \>=15 mmHg; high, \>115 mmHg or \>=105 mmHg and increase from baseline \>=15 mmHg.

Time frame:
52 weeks
Reported as:
Number · participants
Number of Patients With Newly Occurring or Worsening Clinically Notable Vital Signs Values at Any Timepoint Over the Whole Treatment Period
participantsNVA237Tiotropium
Pulse rate - low01
Pulse rate - high00
Pulse rate - low or high01
Systolic blood pressure - low00
Systolic blood pressure - high10
Systolic blood pressure - low or high10
Diastolic blood pressure - low10
Diastolic blood pressure - high20
Diastolic blood pressure - low or high30
SecondaryNumber of Patients With Notable Change From Baseline in Fridericia's QTc Values at Any Timepoint Over the Whole Treatment Period

Clinically notable change from baseline was and increase from baseline of 30 or greater milliseconds (ms).

Time frame:
52 weeks
Reported as:
Number · participants
Number of Patients With Notable Change From Baseline in Fridericia's QTc Values at Any Timepoint Over the Whole Treatment Period
participantsNVA237Tiotropium
Increase from baseline 30 to 60 ms61
Increase from baseline >60 ms20

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NVA237—16/123 (13%)83/123 (67.5%)
Tiotropium—6/40 (15%)33/40 (82.5%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventNVA237Tiotropium
PneumoniaInfections and infestations0/1232/40
Angina unstableCardiac disorders0/1231/40
Bile duct stoneHepatobiliary disorders0/1231/40
ContusionInjury, poisoning and procedural complications0/1231/40
Heat illnessInjury, poisoning and procedural complications0/1231/40
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1231/40
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders2/1230/40
Cardiac failureCardiac disorders1/1230/40
CataractEye disorders1/1230/40
Macular holeEye disorders1/1230/40
Most frequent other events
Showing 10 of 79
Most frequent other events
EventNVA237Tiotropium
NasopharyngitisInfections and infestations37/12313/40
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders28/12313/40
BronchitisInfections and infestations6/1235/40
HypertensionVascular disorders7/1235/40
ConstipationGastrointestinal disorders6/1233/40
GastritisGastrointestinal disorders1/1233/40
Upper respiratory tract infectionInfections and infestations6/1233/40
VertigoEar and labyrinth disorders2/1232/40
Dry mouthGastrointestinal disorders2/1232/40
ToothacheGastrointestinal disorders1/1232/40

Baseline characteristics

Age Continuous
Age Continuous(years)NVA237TiotropiumTotal
Mean68.4 ± 7.2969.4 ± 7.4868.7 ± 7.32
Sex: Female, Male
Sex: Female, Male(Participants)NVA237TiotropiumTotal
Female224
Male12138159
08

Study locations

40 sites
  • Novartis Investigative Site
    Iizuka, Fukuoka 820-8505, Japan
  • Novartis Investigative Site
    Kitakyushu, Fukuoka 802-0083, Japan
  • Novartis Investigative Site
    Kitakyushu, Fukuoka 820-0052, Japan
  • Novartis Investigative Site
    Kurume, Fukuoka 830-0011, Japan
  • Novartis Investigative Site
    Onojo, Fukuoka 816-0931, Japan
  • Novartis Investigative Site
    Yanagawa, Fukuoka 832-0059, Japan
  • Novartis Investigative Site
    Asahikawa, Hokkaido 070-8644, Japan
  • Novartis Investigative Site
    Obihiro, Hokkaido 080-0805, Japan
  • Novartis Investigative Site
    Sapporo, Hokkaido 060-8648, Japan
  • Novartis Investigative Site
    Himeji-city, Hyogo 672-8064, Japan
  • Novartis Investigative Site
    Takarazuka, Hyogo 665-0827, Japan
  • Novartis Investigative Site
    Yabu, Hyogo 667-8555, Japan
  • Novartis Investigative Site
    Inashiki-gun, Ibaraki 300-0395, Japan
  • Novartis Investigative Site
    Naka-gun, Ibaraki 319-1113, Japan
  • Novartis Investigative Site
    Sashima-gun, Ibaraki 306-0433, Japan
  • Novartis Investigative Site
    Morioka, Iwate 020-0055, Japan
  • Novartis Investigative Site
    Kawasaki, Kanagawa 210-0852, Japan
  • Novartis Investigative Site
    Yokohama, Kanagawa 232-0021, Japan
  • Novartis Investigative Site
    Yokohama, Kanagawa 236-0051, Japan
  • Novartis Investigative Site
    Uji, Kyoto 611-0042, Japan
  • Novartis Investigative Site
    Matsusaka-city, Mie 515-8544, Japan
  • Novartis Investigative Site
    Sendai, Miyagi 981-8563, Japan
  • Novartis Investigative Site
    Nagaoka-City, Niigata 940-2085, Japan
  • Novartis Investigative Site
    Nagaoka, Niigata 940-8653, Japan
  • Novartis Investigative Site
    Kasaoka, Okayama 714-0081, Japan
  • Novartis Investigative Site
    Tsuyama, Okayama 708-0841, Japan
  • Novartis Investigative Site
    Osakasayama, Osaka 589-0022, Japan
  • Novartis Investigative Site
    Sakai, Osaka 591-8555, Japan
  • Novartis Investigative Site
    Takatsuki, Osaka 569-1096, Japan
  • Novartis Investigative Site
    Shimotsuka-gun, Tochigi 321-0293, Japan
  • Novartis Investigative Site
    Bunkyo-ku, Tokyo 113-8431, Japan
  • Novartis Investigative Site
    Nakano-ku, Tokyo 164-0012, Japan
  • Novartis Investigative Site
    Ohta-ku, Tokyo 140-0063, Japan
  • Novartis Investigative Site
    Yamagata city, Yamagata 990-8533, Japan
  • Novartis Investigative Site
    Ube, Yamaguchi 755-0241, Japan
  • Novartis Investigative Site
    Fukuoka, 812-0033, Japan
  • Novartis Investigative Site
    Kochi, 780-8077, Japan
  • Novartis Investigative Site
    Osaka, 530-0012, Japan
  • Novartis Investigative Site
    Osaka, 545-8586, Japan
  • Novartis Investigative Site
    Saitama, 337-0012, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010 and a primary completion of Nov 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2010
First posted
May 10, 2010
Start
May 2010
Primary completionActual
Nov 2011
Results first posted
Jan 18, 2013
Last update
Jan 18, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01119937
Responsible party
Sponsor
First posted
May 10, 2010
Start date
May 2010
Primary completion
Nov 2011
Results posted
Jan 18, 2013
Last update
Jan 18, 2013

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glycopyrrolate · Tiotropium

Start the discussion